Bendova Pharmaceuticals

Many other drugs also lose patent protection leading to the creation of substitutes that are cheaper.

Pharmaceutical companies are provided with temporary monopoly rights on the production of new drugs which result in a higher cost on consumers. If competing companies were allowed to produce generic forms of those drugs, consumers will be able to afford those medications even in cases where those consumers have no insurance coverage. The company responsible for developing and inventing the original medication could be offered incentives to invent in the future by either obtaining tax breaks or NIH funding for future research. They could even be offered a percentage of the sales of the generic drugs. Economist Gary S. Becker advocates dropping many FDA requirements that, in his opinion, provide no additional safety measures but rather delay the development of new drugs.[12] Betamethasone, for example, has been part of the standard prenatal care in Europe since the late 1970’s while it got adopted in the U.S. after 1997. On many occasions, the FDA ignores all scientific evidence concerning certain drugs because the manufacturer did not follow their mandated bureaucratic standards.

I think Big Pharma companies skew their data very regularly. Although this is not ethical, it's practiced in this field because there is a certain probability calculated as it relates to side effects and ineffectiveness. For instance when we take Tylenol as a child we eventually become tolerant to the dosage. As we get older we need to increase the dosage even more than is advertised to get relief. The Pharma companies do not advertise that ALL pills have a toxicity level and will affect our organs at some point in time. Each pill is tested for toxicity levels before being released to the public. With that said, these companies take on a certain amount of acceptable risk when producing medication. The public has accepted this risk with

Questions for the Harvard case “Metabical: Pricing, Packaging, and Demand Forecasting for a New Weight-Loss Drug”

Pharmaceuticals in the United States have been on the rise for years and everyone is trying to find was to get cheaper medication. New generics, 4 dollar lists, and coupons have been a growing force in pharmacies in the past few years. Some might think, “There has to be laws against rising prices, right?” Well, sort of.

He’s an up and comer in a mindless, cavernous sea of pencil-pushers. A massive skyscraper monstrosity of offices and desks is home to a young man working tirelessly to move up the corporate ladder of Consolidated Life Insurance. This young man, C.C. Baxter, is willing to do whatever it takes to climb each rung of success. Luckily for him, Mr. Baxter is popular among some of the more influential executives. However, this isn’t just because he’s a hard worker with a likeable personality.

Another issue is too much power is given to scientists in decision-making of candidate drugs. Also there were inadequacies and lack of communication between marketing and research. Merck’s marketing and research needed to realize that the making of the drug is not only the most important part in increasing sales, but it also included a strong advertising campaign that will satisfy the needs of the customers.

The first compensation package offered to Dunlap (the 1996 – 1997 compensation package) was well designed in the consideration of merely improving the stock prices and the company’s market value in the short term. It consists of a salary of 507,054, no bonus but well over 16 millions in stock options. The package design was obviously shortsighted and focused primarily on the profits and share value as expected and lacked incentive to create long-term value. The company’s other values, such as culture, employees and customers had absolutely no value in this model. Furthermore, the package even encouraged Dunlap to forego long-term initiatives at the expense of employee’s benefits and the company’s social responsibility and long-term profitability in order to drive up the stock price.

departments and shareholders. Practically all of the stakeholders in the business are involved. Major exception is the customers on whose interest the whole meetings are usually based on anyway. Work councils are defined as instituting information flow, increased trust, best practices in the industry, cooperation and industrial up-gradation (Brewster et al., 2007). Work councils are a more modern approach for the non-unionized employee voice and are mainly used in the west. Good example of such companies will be Rio Tinto or Pfizer.

While this case is literally full of negative aspects, we will only focus on the main points for both arguments. Pharmaceutical companies want to be sure that the products they spend years and millions of dollars to create are not easily reproduced and sold at discount prices. The profits pharmaceuticals make of their patented products are supposed to refinance new research. So taking away their exclusive distribution rights and allowing other manufacturers to just copy the product and sell it at

In mid-September 2005, Ashley Swenson, the CFO of large CAD/CAM equipment producer must choose whether to pay out profits to the firm¡¦s investors or repurchase stock. On the off chance that Swenson pays out profits, she should likewise settle on the extent of the payout.

* Competitive Pricing – Merck is sometimes forced to lower prices of products, either ones that have gone off patent to maintain market share in the product, as well as for products that are still on patent in order to compete with rival products for the same treatment that are marketed by competitors

Pharmaceutical companies should attempt to be as transparent as possible when marketing prescription drugs to the public. Their marketing efforts should not only convey the benefits of the prescription drug, but also easily convey the possible risks associated with the prescription drugs. Many patients may tend to think the benefits outweigh the potential risks of prescription drugs and may pressure their physician to prescribe it. Due to the way the prescription drug is marketed, the consumer may believe the

In 2005, Phillip (Phil) Landgraf faced several glaring problems in the financial performance of his company, BioPharma, Inc. The firm had experienced a steep decline in profits and very high costs at its plants in Germany and Japan. Landgraf, the company 's president for worldwide operations, knew that demand for the company 's products was stable across the globe. As a result, the surplus capacity in his global production network looked like a luxury he could no longer afford.

activities and tactics such as sampling and sales force promotion [3]. Whether a brand manager is using right promotional tools, whether 4P`s (now 7P`s are considered) are linked to each other and with product strategies for the two main objectives that includes [3]:  To Generate Prescription  Make the product reach the patient They can be said as Product chain and Prescription chain 1.1 The Product Chin This starts from selection of molecules and ends in the hands of patient. This chain is somehow intensive as it starts from the selection of molecules, then molecules are critically screened, after the screening of molecules the source of raw material is identified then the pilot batch manufacturing process starts at this stage pricing strategies and clinical trials are worked out. Once the pilot batch is manufactured then it starts with the commercialization of product, after commercialization product goes to distribution house and then it reaches the retailers. After patient’s diagnosis by doctor, patient purchases that product from retailer [4]. 1.2